Notably, pharmacological targeting of CRABP2 using SNIPER-11 reduces cholesterol content, suppresses AKT activation, and sensitises tumours to gemcitabine both in vitro and in patient-derived xenograft models [65]. Here, AKT1 is linked to neoplasm.